enzymatic assay for ethylene glycol, however, has not been previously documented. The interference may not have been appreciated in previous evaluations of the assay because test compounds, such as lactate and alcohols, were added to normal serum, not sera from critically ill patients [2]. To evaluate the performance of the enzymatic assays for ethylene glycol and ethanol in hospitalized patients with abnormal serum chemistry, we added D-lactic acid to two random serum samples with markedly increased LD and performed the enzymatic assays (Table 1). Lactate per se does not interfere in the assay; however, the concomitant presence of LD under the proper assay conditions produces NADH, resulting in substantial false-positive values in the enzymatic assays for ethylene glycol and ethanol. Given their correlation with the concentrations of LD and lactic acid, these false-positive values may be due to the LD-catalyzed conversion of serum lactate and reagent NAD to pyruvate and NADH.

To support this hypothesis, we reconstituted normal serum with increasing concentrations of LD-5 purified from human placenta (Sigma Chemical Co., St. Louis, MO) in the presence of 0, 10, or 50 mmol/L D-lactic acid (Sigma). The ethylene glycol enzymatic assay gave falsely positive results when LD serum activity was >3000 U/L, as did the ethanol enzymatic assay when LD serum activity was >2000 U/L (Fig. 1). The interference was most pronounced when the concentration of D-lactate exceeded 10 mmol/L. These data, however, should not be strictly extrapolated to the clinical setting because the contribution to total LD activity in this experiment was due solely to LD-5, and the concentration of lactate consisted of approximately equal amounts of L- and D-isomers. In hospitalized patients, increased LD activity may be due primarily to the contribution of a different isoenzyme or of more than one isoenzyme, and increased lactate concentration will most probably be the L-isomer. However, the data obtained from three hospitalized patients with increased serum LD activity (Table 1) support a clinically relevant guideline that significant false-positive results occur when the LD serum activity is at least 12-fold greater than the upper limit of the reference interval, and lactate is concomitantly at least 10-fold greater than the upper limit of its reference interval.

High concentrations of lactate and LD in sera from critically ill patients interfered in the enzymatic assay for ethylene glycol by increasing the production of NADH. Although lactate added to normal sera does not interfere with the assay, results should be interpreted cautiously in samples with high LD and lactate concentrations. Other interferences reported for the ethylene glycol enzymatic assay include glyceraldehyde and glycerol, which can be oxidized by the enzyme glycerol dehydrogenase [2]. The enzymatic assay is otherwise very specific, and other alcohols—including ethanol, methanol, and isopropanol—do not interfere with interpretation. Ethylene glycol poisoning of previously healthy individuals may result in lactic acidosis but will not typically result in increased LD. However, this analytical interference becomes clinically relevant in cases of suspected ethylene glycol poisoning of individuals with hepatic, renal, or cardiac disease who may manifest both lactic acidosis and increased serum LD. Positive results in the enzymatic assay for ethylene glycol in such cases should be confirmed with a different method such as gas chromatography.

We thank Brian Gilmore for expert technical assistance.

References


According to the recommendations of the National Cholesterol Education Program Adult Treatment Panel, low-density lipoprotein cholesterol (LDL-chol) should be used for screening and as a primary treatment criterion for patients with increased total cholesterol concentrations [1]. This makes the need for accurate measurements of LDL-chol a national public health imperative. The use of the Friedewald equation is attractive, but its accuracy is in doubt in plasma samples with triglyceride (TG) concentrations >4.5 mmol/L (400 mg/dL) [2-7]. A decade ago we found the Friedewald equation to be accurate up to a TG concentration of 8 mmol/L [8]. Assuming that similar plasma samples were analyzed, these findings raise questions about the quality of the methods used in other laboratories, especially in the analysis of hypertriglyceridemic samples. The disposal of a direct LDL-chol method not interfered with by hypertriglyceridemia [9] prompted us to evaluate its accuracy in hyperlipidemic samples, including a selection with familial dysbetalipoproteinemia (FD). We hoped that this reevaluation could shed more light on our previously reported claim concerning the accuracy of the Friedewald calculation compared with that of the reference method [8].

We thank Brian Gilmore for expert technical assistance.

References

Clinical Chemistry 42, No. 9, 1996


According to the recommendations of the National Cholesterol Education Program Adult Treatment Panel, low-density lipoprotein cholesterol (LDL-chol) should be used for screening and as a primary treatment criterion for patients with increased total cholesterol concentrations [1]. This makes the need for accurate measurements of LDL-chol a national public health imperative. The use of the Friedewald equation is attractive, but its accuracy is in doubt in plasma samples with triglyceride (TG) concentrations >4.5 mmol/L (400 mg/dL) [2-7]. A decade ago we found the Friedewald equation to be accurate up to a TG concentration of 8 mmol/L [8]. Assuming that similar plasma samples were analyzed, these findings raise questions about the quality of the methods used in other laboratories, especially in the analysis of hypertriglyceridemic samples. The disposal of a direct LDL-chol method not interfered with by hypertriglyceridemia [9] prompted us to evaluate its accuracy in hyperlipidemic samples, including a selection with familial dysbetalipoproteinemia (FD). We hoped that this reevaluation could shed more light on our previously reported claim concerning the accuracy of the Friedewald calculation compared with that of the reference method [8].

We thank Brian Gilmore for expert technical assistance.

References
samples of the subjects studied. We used a calibrating serum for statistical results: mean \( y \), 4.01 ± 1.98 mmol/L; mean \( x \), 3.81 ± 1.98 mmol/L. Additionally, other conditions were similar to the macro procedure applied before freezing. As could be derived from the calibration method, it was found to be essential for the assay.

The reference method we used was a combined ultracentrifugation/precipitation procedure. VLDL-cholesterol was determined directly in the VLDL isolated by sequential ultracentrifugation [13]. After ultracentrifugation of plasma in the TFF 45.6 rotor (Kontron, Zürich, Switzerland) for 16 h at 131,000 g in the Beckman L-7-55 ultracentrifuge at 14 °C, the density 0.906 g/L fraction was aspirated by means of a rubber bulb Pasteur pipette. LDL-cholesterol was determined in plasma after precipitation of the VLDL and LDL with phosphotungstic acid and MgCl₂ (cat. no. 543004; Boehringer Mannheim, Mannheim, Germany). LDL-cholesterol was calculated by subtraction. Reproducibility, expressed as the CV, was 4.3% for VLDL-cholesterol determination, 2.6% for LDL-cholesterol determination, and 2.3% for LDL-cholesterol calculation (n = 30).

The LDL-immunoassay reagent was obtained from Sigma (Sigma LDL-cholesterol, cat. no. 353-A, lot no. 05516275; St. Louis, MO). The procedure was performed according to the manufacturer's directions. The LDL-cholesterol reagent consists of a suspension of polystyrene latex beads coated with goat polyclonal antibodies to human apoproteins in a buffer containing 1 g/L sodium azide. From this reagent 200 μL is pipetted into the inner compartment of a separation tube (fitted ultracentrifugation tubes); to the same compartment we added 30 μL of either the controls (concentrations low and high, included in the kit) or plasma, capped the tubes, and vortex-mixed them. After incubation for 5 to 10 min at room temperature, we centrifuged the tubes for 10 min at 4300 g at room temperature. Subsequently, the filtrate in the outer compartment was vortex-mixed and assayed for cholesterol. Although the vortex-mixing step was not mentioned in the prescription of the supplier, it was found to be essential for obtaining precise results. The cholesterol concentration determined in the filtrate was multiplied by 7.35 to obtain the LDL-cholesterol concentration in plasma. The precision, as expressed by the interassay CV, was 5.8% and 4.9% for the low- and high-concentration control, respectively (n = 10).

As mentioned before [8], the accuracy of the Friedewald formula (LDL-cholesterol = total cholesterol - HDL-cholesterol - 0.45 × plasma triglycerides) is influenced by the accuracy of the methods used for the determination of cholesterol, TG, and HDL-cholesterol. Furthermore, the relation between the concentration of plasma TG and VLDL-cholesterol is dependent on age, sex, and sociodemographic variations of the subjects studied [14]. For most accurate results we used a value of 0.42 × TG as the best approach for VLDL-cholesterol [8].

Cholesterol was determined (with the reagent of Boehringer Mannheim, cat. no. 1489704) on the Hitachi 747 analyzer. For samples containing HDL, a micro method was used, in which 20 μL of sample was mixed with 250 μL of reagent for 10 min. Other conditions were similar to the macro procedure applied for total plasma cholesterol. We used a calibrating serum for automated systems (Boehringer Mannheim cat. no. 759330). The accuracy of the procedure was checked against the improved Abell–Kendall procedure and the bias was <0.3%; precision was 1.9% (n = 30). TG were analyzed on the Hitachi 747; the accuracy was checked against a semiautomated colorimetric method [15]; precision was 1.6% (n = 30) for concentrations up to 12 mmol/L. The accuracy of the HDL-cholesterol method was confirmed by comparison with sequential ultracentrifugation and against the polyethylene glycol-6000 precipitation method (16, 17) and unpublished observations. The HDL-method used appeared to be very convenient for normo- and hyperlipidemic plasma in that very few samples had to be ultrafiltered to clear turbid supernates.

Results were analyzed by Student's paired t-test. Results obtained by different methods were correlated by using Pearson's correlation test with the application of the SSPS/PC statistical software (version 3.1) (SSPS, Chicago, IL). The standard errors in the intercept, slope, and estimate \( S^\text{est} \) were also calculated by using the test of Passing and Bablock [8]. For all intermethod comparisons the deviations in intercept and slope did not deviate from the ideal curve \( y = x \). Differences were considered significant at \( P < 0.05 \).

We applied the various methods for determining LDL-cholesterol in 217 fresh plasma samples with TG concentrations ranging from 0.41 to 50.1 mmol/L including 31 samples with a concentration >8.0 mmol/L and 11 samples of subjects with obligate FD with VLDL-cholesterol/TG ratio >0.69. The results obtained with the LDL direct method agreed better with the reference method than the estimated LDL-cholesterol values (correlation coefficients 0.94 vs 0.85, \( S^\text{est} \) values 0.34 vs 0.55, respectively). After exclusion of the samples with plasma TG >8.0 mmol/L and the samples of the patients with FD (all having a VLDL-cholesterol/plasma TG ratio >0.69), the results (n = 177) obtained with the Friedewald equation correlated very well with the reference method, similarly as those obtained with the LDL-direct method (n = 115) (correlation coefficients >0.97, \( S^\text{est} \) values <0.21, regression equations by Passing and Bablock analysis not different from \( x = y \)). These results are in agreement with those reported previously [8]. Results obtained for the non-FD plasma samples with TG concentrations between 4 and 8 mmol/L were explicitly similar to the general mean results (data not shown). These findings can be explained by the relative constancy of the ratio VLDL-cholesterol/plasma TG in the plasma samples with TG concentrations up to 14 mmol/L (Fig. 1). Thus, we did not obtain evidence for a shift in the chemical composition data as a result of an excess of chylomicrons at increasing plasma TG values.

In the non-FD samples with TG <8.0 mmol/L, in which the Friedewald approach gave accurate values, internmethod precision of the Friedewald–ultracentrifugation comparison and the direct LDL–ultracentrifugation comparison were similar (\( S^\text{est} \) values 0.17 vs 0.21, respectively).

A negative bias of –11% was obtained with the direct method (\( y \)) after prior storage of the plasma samples at –80 °C compared with the reference method (\( x \)): mean \( x \), 4.12 ± 1.98 mmol/L; mean \( y \), 3.58 ± 1.75 mmol/L; linear regression equation \( y = 0.88x - 0.02 \), correlation coefficient \( r = 0.93 \), \( S^\text{est} \) = 0.35, n = 110. Apparently, some of the LDL was retained in the column. Addition of 6 g of saccharose per liter of plasma before freezing prevented this, as could be derived from the statistical results: mean \( x \), 4.01 ± 1.98 mmol/L; mean \( y \), 3.81 ±
ported by the results of McNamara et al. Hypertriglyceridemic plasma samples are analyzed. This is supported by the relativity constant estimate for VLDL-cholesterol that we observed, independent of the plasma TG concentration. Our observations suggest that in other laboratories one of the analytical methods delivering values for substitution in the Friedewald formula is biased or imprecise, especially when hypertriglyceremic plasma samples are analyzed. This is supported by the results of McNamara et al. [2]: At TG concentrations >4.00 g/L (4.5 mmol/L), large standard deviations prevent the drawing of conclusions concerning the optimal estimation factor (TG/4.5 to TG/8) as an approach for VLDL-cholesterol, in contrast to our results. We can only speculate which of the methods is responsible for the reported large variation of the bias between estimated and measured LDL-cholesterol values. It is generally known that HDL-cholesterol analysis in hypertriglyceridemic plasma samples is potentially biased because of possible incomplete removal of the apo B-containing lipoproteins [19]. Theoretically, also, the method for the determination of TG may be biased in hypertriglyceridemic samples. Standardization on the basis of the CDC protocol does not exclude this, because only normo- or slightly hyperlipidemic controls have to be analyzed in this program. Because of the lack of suitable control material, the quality of the analyses at higher degrees of lipemia is at present uncertain. This is more true in methods requiring lipemic samples to be serially diluted for proper calibration. It is also possible, as already suggested by Friedewald et al. [20], that the reference method is biased or imprecise when hypertriglyceridemic plasma samples are analyzed. To prevent this we determined VLDL-cholesterol directly, whereas most other laboratories determine VLDL-cholesterol indirectly as the difference of total cholesterol and the cholesterol present in the d >1.006 kg/L fraction. The latter procedure can result in variable VLDL-cholesterol concentrations involving imprecise cholesterol analysis. In the same way, relatively large CVs of the methods used in these evaluations underestimate the bias in LDL-cholesterol of the Friedewald approach, especially for lipemic plasma. In plasma samples with TG >8.0 mmol/L the direct method is preferred over the Friedewald approach. Until now, large-scale use of the direct method is prevented by the instability of the analyte when stored frozen [20]. Irrespective of the value of any method in the risk estimation for coronary heart disease, the support of a lipid reference laboratory remains necessary because of the limited value of both the Friedewald approach and the direct LDL-method for proper phenotyping of strongly hyperlipidemic samples. Considering the fact that the measured plasma triglyceride concentration also gives insight into the LDL, reportedly being associated with increased atherogenesis [23, 24], the use of the Friedewald formula is recommended up to a TG concentration of 8 mmol/L.

We thank Sigma Diagnostics for providing the reagents of the immunoassay kit.

References

Coronary atherosclerosis occurs twice as frequently in patients with hypothyroidism as in age- and sex-matched controls [5]. Because of their increased tendency to develop hypertension and hypercholesterolemia, hypothyroid patients are predisposed to coronary artery disease and subsequently to myocardial infarction. Saito et al. found that hypertension was more frequent in hypothyroid patients than in age-matched euthyroid persons [6]. Also, cholesterol-fed animals with hypothyroidism developed accelerated atherosclerosis that is reduced after thyroid hormone replacement [7]. These observations suggest that the concomitant occurrence of ischemic heart disease and hypothyroidism will be a recurring concern.

Recently, the new markers troponin T and troponin I (Tn-I) have been extensively studied because of their cardiac specificity. Their concentrations increase within 6 h of myocardial injury and remain increased for as long as 7 days. However, increased concentrations of troponin T have also been found in polymyositis/dermatomyositis [8], renal failure [9], trauma [10], and rhabdomyolysis [10], whereas no increase in Tn-I is seen in patients with rhabdomyolysis, multiple trauma, chronic muscle disease, chronic renal failure, or in marathon runners [11-15]. Given the apparent lack of published reports on Tn-I values in hypothyroidism and in view of the difficulty in interpreting CK and CK-MB, we studied the effect of hypothyroidism on Tn-I.

A case that illustrated the above points and was the impetus for this study was that of a 55-year-old white man who presented to the hospital with the complaint of intermittent left-side chest pain and progressive shortness of breath and edema for 6 months. He had a history of an anterosetal myocardial infarction in 1982 and complained of constipation and weight gain. Chest x-ray revealed cardiomegaly and congestive failure, and echocardiogram showed a pericardial effusion. Laboratory values were as follows: CK 9160 U/L (reference range 50-150 U/L), CK-MB 21 μg/L (reference range 0-4 μg/L), and cardiac Tn-I <0.4 μg/L (reference range <0.4 μg/L). On the basis of these findings, he was ruled out for acute myocardial infarction.

Subsequently, we reviewed 52 consecutive patients presenting to Parkland Memorial Hospital in late January and early February 1996 in whom a troponin (TnI) value >25 mU/L was observed (reference range 0.4-4.5 mU/L). The procedures we followed were within the standards set by the Ethics Committee of our institute. Because this was a laboratory-initiated study, we cannot report on the severity of the hypothyroidism based on clinical findings, and the findings in this study should be interpreted in that light. Most of these patients were seen in the outpatient clinic for management of their hypothyroid state. Various etiologies of hypothyroidism were observed. Two patients had atypical chest pain, but infarction was excluded. Ages ranged from 26 to 70 years (mean 46), an age group not uncommonly encountered in the evaluation of ischemic heart disease. The patients studied were 42 women and 10 men. TSH values ranged from 25.1 to 295.5 mU/L (mean 79.7). Free thyroxine (FT4) values ranged from undetectable to 12.9 pmol/L (reference range 10.3-23.2 pmol/L). The same sample used to measure TSH and FT4 was also used to measure CK, CK-MB, cholesterol, and cardiac Tn-I. TSH and FT4 were measured on the Ciba Corning (Medfield, MA) ACS:180® with an immuno-